Esperion Therapeutics (ESPR) 3 May 222022 Q1 Earnings call transcript

Company Profile

Participants

Tiffany Aldrich	Senior Manager, Corporate Communications
Sheldon Koenig	President and Chief Executive Officer
Joanne Foody	Chief Medical Officer
Eric Warren	Chief Commercial Officer
BJ Swartz	Chief Strategy Officer
Serge Belanger	Needham
Jason Butler	JMP Securities
Jessica Fye	JPMorgan
Jeff Hung	Morgan Stanley
Joseph Thome	Cowen
Paul Choi	Goldman Sachs
Emanuela Branchetti	H.C. Wainwright
Judah Frommer	Credit Suisse

Call transcript

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by and welcome. [Operator Instructions] Please be advised that today’s conference call may be recorded. I would now like to hand the conference over to Tiffany Aldrich, Senior Manager in Corporate Communications at Esperion. Please go ahead.

Tiffany Aldrich

Thank you. to conference quarter call. welcome and financial and update company morning Esperion’s XXXX first results Good I of team the Tiffany Corporate am Aldrich Communications here and at I’m part Esperion. the callers Harbor Safe of the Reform information to under Litigation provisions that Securities want is covered remind discussed I on Act. call Private today the the listeners that making I will caution forward-looking statements. be management associated Actual due to statements by our results could forward-looking differ materially and from with uncertainties those business. stated or implied the risks statements cautionary in in their entirety release forward-looking our today’s These are and the press statements qualified by contained SEC filings. call of this this time-sensitive content XXXX. accurate The is May only broadcast, of conference of contains date information the that X, as live We reflect and conference no forward-looking call to circumstances any of update statements events this undertake webcast. to revise after obligation or or the date

being can this content call www.esperion.com found archived. this a and webcast press copy are the within morning Investors issued Media detailing As A be and We call. recorded section. a release and at the today’s conference of reminder,

with question. We will your call prepared the open begin for then and comments

over call, the call team to Strategy President Sheldon? follow-up Sheldon BJ for Officer. corporateteam@esperion.com prepared CEO; Koenig, e-mail speak are now Foody, today’s time Joanne Chief Medical Officer; the today turn Chief available to Chief Warren, Commercial be Dr. Officer; to us remarks. Please the schedule questions. with and for Sheldon Eric Swartz, team. will With Following and I some will

Sheldon Koenig

good everyone. and Tiffany, morning, you, Thank

year of goals Esperion here our be will and to excited today transformational recap XXXX. first are you for for what We to the be a with quarter reaffirm

and both to becoming and our our to outlined has continued in the cardiometabolic to few of company execute Over a commercially quarters, Esperion we the for goal innovative growth long-term And vision leader. position success. an attain clinic strategic past

we unprecedented Outcomes quarter advancement growth NEXLIZET, up operational the of XXXX. trial, our XXXX, ongoing to the products, our As to our resources line our driving CLEAR readout of of in and and first streamlined structure the the consistent on planned top focus that commercial strategy, part of NEXLETOL leading in

quarter, we focused and and overview our first last begin are million, of Now of net period from we the approximately and To XXXX. commercial delivering same demand were refined U.S. programs support the XXXX These the NEXLETOL quarter, of recap with and results robust with in the remainder product of objectives. of XXXX, $XX.X revenue year-over-year initiated like the culmination during the product medicines in grew these remain to progress improve. a to NEXLIZET. up positioning brief of patient continue I’d steadfast the enhanced XXX% on XX.X% for

utilization. optimize We frequent even further physician have identify more and organization who enhanced the began will deploying physicians targeting help efforts contract drive this using year, new to sales on concentrating our targets we

NILEMDO NUSTENDI Our least partners, through Daiichi at quarter actively to Sankyo grow the their in Europe, patients XX,XXX European have and of territory and continue treated XXXX. first cumulatively

of plan care. announced pleased our execution quarter to the in operational achieved expenses also XX% medication oral of that effective have year-over-year first Our savings believe an inhibitors. products the traction provide launch accessibility cost transformative European our continue to with report I to of demonstrated PCSKX this significant patient stronger market the than am trajectory we a improvement of the convenience will quarter compared This and to have in the XXXX. fall. And quality represents that in a significant we of

MACE to the with accumulation XX% CLEAR end We of in top XXX% line and trial year, of first of the are by quarter data in reach approaching Outcomes our unprecedented MACE the expect XXXX.

by to mission an manufacturers team for high-quality Esperion. $XX drug annual With data oral and patients in to trial of estimated cholesterol realized ensuring value risk. is therapies billion. to address accessible a XX proper significant alone, to close see By cardiovascular And for our the evidence also NEXLIZET patients a supporting the heart U.S. Esperion projected effects LDL-cholesterol California to this impacted will existing delivery We be know, on lipid is reducing in of recently the more These a healthcare the unable in guideline task ever the crucial and all patients extensive globally, million As collaborative study attack. focused priority identify waiting estimated remains recommended numerous cholesterol entire hypercholesterolemia system XX XXXX, Northern collection. you who a their million critical options achieve despite to is is are support exceed management learning the of not patients LDL the treatment management. data than the revenue value cardiovascular a of in LDL treatment clinical add market treat with and committed to in levels worldwide cholesterol NEXLIZET. its the integrated body study announced XX% landscape. to options. in large providing at of goals Other with of and are following it Presently, an

to clinical presentations. over Joanne? Joanne and of for activities turn to overview the data Now I’d like an call our ongoing

Joanne Foody

cause in Sheldon. begin like COVID-XX pandemic. staggering death the on recent the to losses heart years disease of I’d disease by you, United COVID, life expectancy leading the emphasizing the in impacts in Thank of U.S., Despite States. during remains severe the cardiovascular from particularly the

reaffirm therapies disease, high franchise. by added commercial to importance bempedoic LDL bring ongoing attributed These and atherosclerotic and statistics medical in its fact, pandemic. to risen XXXX, that XXXX transformational years contributing of cardiovascular disease from In and chronic expectancy are sobering It stroke XX% rates cardiovascular to disease diseases the efforts heart heart all X.X% cholesterol. Esperion’s urgency a is large to our tests to part onset death sharply mortality to reaffirmed mission highlight from They of since driven patients. almost Age of disease clinical tackling life our loss adjusted to acid X supporting increased COVID-XX and during the important period. have of the oral of rates

We we extremely be are to projected estate leveraging novel competitive scientific multibillion XXXX. data, our in a patent the unique to market advance compounds, of mechanisms expect for and pipeline dollar of lipid other also actions which

We you next-generation to end will citrate inhibitors more year. ATP by share PCSKX of lyase the with oral the and on platform have our

to Outcomes collected progress we CLEAR modern evolving trial represents unprecedented medical set Our and today’s expected continues in data as the care most environment. outcome

study is patient that largest Outcomes is ability bempedoic trials of partnership The XX% As is is and developed trialists, adverse CLEAR a to assess experts. unable a yet. outcome current acid’s unique and in in Nissen reminder, reduce the adequately to will one by regulators cardiovascular events. of incidents XX,XXX LDL-cholesterol outcome approaching population nonstatin trial, randomized and a patient care. team of This a with therapies their adverse required of experts major the study risk was The with of events headed world-renowned its address international cardiac Steven standard of trial Dr.

also XXX% our XXXX this all. A Esperion’s Our MACE-X year quarter current to but a acid CV around cardiovascular potential practice-changing label in the and team the be only more is advancing experienced bempedoic A be events since and outcome trial of of the has our shifting make therapy reduction. making the mission deeply of and ensuing LDL-lowering convenient in for positive readout indicated millions committed only XXXX, second one top positive accumulation labeled which reduction first accessible half cardiovascular expects patients of expand line to now not physicians potential of statins year to indication, away. has outcome world, than in the risk for for study paradigm to the for and risk oral less

data our NEXLETOL scientific XXst to Cardiology’s continue meetings. at American presentations also present announced actively Annual We multiple College recently at Session. We Scientific the of on

the and diverse multiple efficacy patient patients journals, of all in benefit and from supporting most our publications likely Additionally, safety populations in bempedoic we data announced therapies. to highlighting peer-reviewed of acid

to back a see, of pass LDL to while commitment for As therapy our understanding the to a our of as advancing Sheldon lipids key commentary results. CLEAR you on our pipeline and executing disease. can it oral and science to cardiovascular progressing cardiometabolic Sheldon? Outcomes, quarterly oral now to of I’ll made address acid address additional bempedoic Esperion cholesterol compounds has

Sheldon Koenig

we XXX% ended continued growth which $X.X revenue previously quarter Royalty year-over-year, for revenue for in the first investor today, March XX, the for approximately XXXX, partner revenue by driven Earlier the XXXX, issued press year-over-year. a results million, XX, containing Netherlands, launched and royalty quarter, product in financial quarter Joanne. was available the was U.S. XX, up territories. March year-over-year. the and website. launches for Switzerland ended XX% our and our XXX% Belgium, you, quarter on first is of approximately grew ended XXXX, Thank $XX.X first March release million up Combined first million, $X.X

NILEMDO and out partner We geographies. continue to expect rolling our to NUSTENDI new

increase was to for the quarter ended approximately Finally, March million $X quarter XXXX, total XX, compared revenue the XXXX, an XXX% million of for year-over-year. first first $XX.X of

expenses, to from margin Turning margin of which our than U.S. in by of revenue, international percent largely as a gross inventory sales. a an our has increase lower purchase the driven partners, decreased

XX% decreases shipments and steady million, of of for when decrease the XX% state SG&A first decrease this year-over-year XX% QX in We was reduction the compared expense expense for alternative related legal quarter, year costs. the XXXX. XXXX. XXXX. onetime These the half implemented million supply $XX.X reached $XX.X quarter in was long-term of reflect for first savings first in transformation year-over-year, manufacturing expect to from success expenses a QX of the over million a improve as to or $XX.X a year-over-year to for adjusting compensation primarily of R&D plan

cash XXXX. for totaled million cash, XX, compared restricted cash XX, $XXX.X As million on and of available with XXXX, March investment equivalents, $XXX.X securities sale December

readout are fund Outcomes anticipated extends CLEAR results. of future operations continues through to capitalized for continuing the our completion and and runway that anticipate foreseeable We the the cash following trial and those well

operating XXXX Our unchanged. the remains guidance year full for expense

today manage risk closing, able line groups maximize and results our their the through our Outcomes foreseeable $XXX to it XXXX February filed our to registration annual positioning expenses within in And to million but alignment to does shelf to to non-cash diligently flexibility depressed recently is medicines expired future. further extremely in to shareholder work reduce our of be anticipate levels $XXX SG&A provide expected million continues believe $XXX mission current accomplished their not be And We and has estimates new during of team has our #X statement CLEAR Outcomes are approximately reducing continue million a continue NEXLETOL the future, critical levels proud of year. I we that NEXLIZET today’s That to the financed trial to cardiovascular between to with killer We stock said, look readout to preserves top can care financial compensation significant organization effectively. help for for These our at in the value. expense are that. registration we of In after the in insight full world. heart what for forward key between benefits $XXX and previous upon of our million $XXX across our the in cholesterol million and patients am patients statement future We to attack stock-based be stroke. for to the trial into this $XX view inclusive provide of filing future price R&D our be our report. patient we million. environment. incurred the filing the and disease year risk Cardiovascular to be ever-important and beyond medical of from belief the CLEAR as the potential change This expenses underrepresented

our productive forward look solid your Q&A. support planned Operator, and for We joining activities, in what update Esperion. interest and additional be year have and execute for Thank on in to we for you a now exciting today and will we us. are on place strategy for an providing ready all continued to

Operator

the Instructions] question Our first your question from [Operator of Michael Jefferies, line comes please. Yee of

Unidentified Analyst

me. Yee. This strong my Thanks on and Mike line a for Maybe congrats morning. the on two taking quarter. Hi, question [indiscernible] for is good

in Daiichi? And into is, each from what sales very Thank impact good could a can CVOT of payments? comment And be for the you your to as all, are you in how is data pandemic? second Specifically, I one see payment you would get well? And on to drive efficacy? increase needs and of could you about quarter comment That how confident to you. second or of the guess clarify talk if the milestone what the volume bar trajectory price? recent a be see Do there you well is are appreciating the kind the the volume you the U.S. for from accelerating First there helpful. maybe could data do scenarios scenarios? is as any on beyond you

Sheldon Koenig

of first Well, good all, Great. morning.

I’ll with start for it to your over to me relates Let your second first Warren Eric question turn question, sales, and as it etcetera.

So again, message. your you for thank

is works meeting. milestone milestone it the the relates the Daiichi be will quarter a the at up to then be the reported data the first being Then CLEAR with the of have ability with As that I and we payments of that’s for again, Sankyo, the line label. also European it filing Sankyo that Daiichi Eric? included million of the from timing to in to committees. will reiterate to want This data Sankyo. how be we conclusion $XXX top is the and major the study data XXXX. into upon But Daiichi will Outcomes of regulatory just But course, line. again top receive

Eric Warren

the and regards absolutely. about we Good Yes, increase. morning volume a thanks growth a With volume to saw of from question. for X.X% perspective,

So year. the throughout the delivering mantra consistent that we’ve with that’s provided growth consistent of

be will the that the team. So mission for

with do We’re so. growth. exponential And unlock we then, CLEAR track of the Outcomes, course, on to

Unidentified Analyst

Great. Thank you.

Sheldon Koenig

Thank you.

Operator

you. Thank

from comes Serge next Our question of Belanger Needham.

Your open. is line

Serge Belanger

Hi, good morning.

couple questions a of me. Just for

contract on The the first sales effort. force one,

to mentioned I been you’ve target able new physicians. you think some

healthcare to you end scaled success with system could a secondly, the guideline the that in So move more down label describe a maybe And up it’s California, a of the positioning with and regarding it Northern just in for up effort it. or can Thank whether be collaborative the then study as extension road? see delivery you.

Sheldon Koenig

Eric?

Eric Warren

Yes. Serge. morning, Good

team, So the form. pilot is CSO as you know, in

to targeted to cover three us: arise; like CSO coverage. the space; some do for feel we banking it’s and HCPs coverage white for overlapping leveraging where dual they the have create essential things to fees cover We’re as

in, We so good. So to team able the meaningful January. in CSO seeing have far, we’re And discussions. to the able late get deployed

scale So encouraging right. environment We’ve upon but And got absolutely depending that in. we upon returns still operate also the depending to see, early, ability you’re so far. that we the the

still pilot So phase. and far, so good, but early in

Joanne Foody

California. for second question Serge, Northern the Thank this your Joanne. is you regarding system in

post point, would this We’re – unlikely pragmatic study attack. really NEXLIZET a approach for indicate would improve To of a label of expansion. for particularly heart be this or allow NEXLIZET to practicing at is syndrome But heart that in ability importantly, coronary this at the looking to clinicians your the utilization discharge of and is is system-level a attack. actually levels it patients that LDL significant time from an acute

believe changing have not important implications, practice-changing a but we that one. that, will label So

Sheldon Koenig

add as acid. to bempedoic out of wealth the already continues there to And relates information to it

about excited that. Thank So Serge. Joanne. you, Thanks,

Serge Belanger

Thank you.

Operator

Thank you.

Butler Jason Our next JMP from Securities. question comes of

open. is line Your

Jason Butler

for Thanks the taking questions.

question. preparing Just in the and us just Can just study. a on growth events physicians you’re you you the database the for in me. couple prescriptions making quarter? And physicians dynamics – events give new with between writing I Can you to where for have commercial you an speak patients then a guess versus on accumulated? of more the Can Thanks. progress new CLEAR update adjudicating Outcomes already adding the the lock-in

Joanne Foody

Jason, thank your So for you question.

well the events. as up XXX% continuing of as events speed, MACE-X real in now On staying of our well events to with to for the are our CVOT, time. adjudicate essentially nearly over MACE-X XX% we Really

continue to will We do that.

which schedule. XX,XXX if Importantly, these over bringing start ahead for end-of-study visit XX,XXX are entire to patients, in and progressing, we global anything, visits, the beginning two of are per the end-of-study study, includes

line of XXXX. than less So look a tuned, top to away. stay QX And year we’re we’re results continuing towards

Eric Warren

your both. we’re commercial regards to seeing with so Jason, it’s Eric, question, then, And

HCPs So This the activity. by are to some driven in mix. the new of is coming digital

approach. As you’re aware, three-pronged we’ve got a

We’re leveraging digital.

personal We’re leveraging promotion, we’re and our leveraging peer-to-peer.

That depth. of We’re encouraging to increased product. deeper promotion also our the levels seeing as result and representatives the of comes a HCPs depth prescribe personal

those of in meaningful gains some So we’ve seen both dynamics.

Jason Butler

Great, the thanks questions. for taking

Sheldon Koenig

you. Thank

Operator

you. Thank

Our Jessica go of ahead. Please next question JPMorgan. from comes Fye

Jessica Fye

my morning. Good for guys. Thanks taking Hey, questions.

on of the one questions. up Following prior

XXX% statin-intolerant trial And NEXLETOL the those and is could so in lowering? more looks patients run LDL assume the a think little by could it net this year? we With the statins additional some color Second then for the rate XX%, third quarter? quarter. in there? so to early need just Or you’re for or of question, reasonable taking more Is gross quarter’s it net more Is they and this use about NEXLIZET improved who continued improvement good last reach is like MACE a CLEAR the where hoping seeing rest accumulation gross today. accumulation question nearing Outcomes on in

Joanne Foody

you your the could to in respect CVOT, that having certainly, With thank year. half Jess, second the of question. earlier for So consider in so the much we XXX%

is The to will study. However, of including end will confident But the depend is though that be close end-of-study of key results that a there those the all amount visits the the top required that closed events. out, study on the significant still QX. time with by we year are out line

Eric Warren

And regards to patients. types the Eric, – with it’s Jess, of

maximally prior statin, and of the ASCVD CLEAR course, that still remained aligns tolerated criteria. with require the population population. reduction, by to Outcomes the label, expand aligns encouraged the very additional So we that LDL-C And potential primary authorization that with it’s

Sheldon Koenig

for Even to thing with that And then, going the Jess, net. ways we we’ve improve to gross regarding GTN. that year, your the fact back look time consistent to been last is our question on this one will

that’s that is continuous. So something

our to continually look always We’re for improve to ways GTN.

our on and shown notable progress. And obviously this concentrate have will focus continue update meetings And the go priority. last that since to a we year, we so. do continue will weekly to improvement we mentioned But as I and you before, on quarters a we have think this. through I we it’s

Jessica Fye

follow-up out, just statin-intolerant their maximum if on that I label, low be even can could dose the statin, of was we patients it no their as within are kind you I statin? hoping maybe max on as tolerated statin Recognizing statins which break of or versus question? phrase on moderate can Eric, patient that to might statin it Great. is no high-intensity tolerated

Eric Warren

that say able to they bulk statins. – able those area physicians underlying are encouraging, the on not promotion from There get just has authorization I’ll Joanne? been level the are of just tried of have the some patients dose not goal, ASCVD. interest a and They focus higher to Yes. the our is from at creates prior in statin we’re perspective. But an those those push that’s challenges levels. have that physicians the HCP that to from

Joanne Foody

I if Jess, some could just provide context. And

in that U.S. I general, Lipitor most commonly lower prescribed, the of is in patients, seeing use even XX the think ASCVD and we’re is in in population, still still the majority that that statin intensity. that.

for if we tolerated maximally that does your Although, say the in intolerance, think statin could our I technically zero. not with label right? – switch allow to point, U.S. you

the However, label. expansive the consistently their statin. of see maximally your group have in the tolerated to broader their remove label Europe, don’t and point, they us tolerated in patients. our and is they And opportunity success part a then to And really target, much statin-intolerant lastly, maximally more for reason the opportunity their that do as irrespective we population, give in of that CVOT that of from being

Jessica Fye

you. Thank

Operator

you. Thank

of Our Stanley. from ahead. go Morgan next Jeff Hung comes Please question

Jeff Hung

my taking questions. for Thanks

to levers additional therapeutic think you’ll of about you to driving you up the prioritizing ACL inhibitor, goal drive that data? the the results. the you Thanks. about the you that growth do And application, next-gen growth any different – indications CVOT of pursue? for broad Outcomes have may talk talked have given how about consistent the further then ahead You Can

Sheldon Koenig

Yes. Jeff. Thanks,

factor COVID has the that with to So play the in growth, obviously, environment consistent we environment. as regards was a

We’re to ability access, to it’s a we’re good There increased us drive sign seeing that a growth. for see. is of greater that’s awareness – in our level starting

activities. the recently live was somewhere X,XXX starting Congress team had attendees. the our up, there neighborhood to Obviously, of for engagement. suite of As think ACC see, that live We’ve X,XXX full a completed in just opens example, Congress world we where the we’re to

the more digital our momentum perspective, more approach. as and creates to continues for So up, doing open that more Obviously, we’re time. world From a X-pronged we’re us. spending

to from with as care continue some to regards momentum to fruit a BJ that maybe expect on Also, that bear perspective, let got well. managed I I’ll we’ve comment So managed care.

BJ Swartz

have geography a analysis we coverage segmentation perspective, standpoint. opportunity each level payer pull-through. favorable done we’ve a And down a a From from commercial Yes. for showing to the

specific perspective that, In addition incremental market HEOR which care should projects we really provide demonstration to as long-term very from embarking as are IDNs growth well well, with into also working as the an as well. on

Sheldon Koenig

partnership just a California would We’ve Northern partnership. well. add, I a I think speaks And with about that institution as to talked

publications to months. seen the are past gain And Joanne, been awareness number that to out these more weeks a of You’ve want do of march growing And continue speak we continue towards also and to... have all as CLEAR. to the few over to completion ways you

Joanne Foody

Absolutely.

for thank question platform. on you much ATP next-generation Jeff, our citrate the So so lyase

multiple disease As we mechanism opportunity that the oncology. you’re one believe cardiovascular moving and and cardiometabolic into across beyond aware, even states has is

you’ve continuing hepatocellular refine diseases well opportunities as kidney disease of are states with and we As stated, such as consideration carcinoma. potential with cardiometabolic even as like diseases oncology disease, in NASH, to

to to can right with we to Stay to data perspective, analytics, respect to us decisions And and investment disease platform, much really citrate this with those expand not respect for but areas, us really a we but help with one. in science, might broader advise with ATP a be patient a international population inhibitors. very the this experts a of the in doing lyase also making we’re commercial the data the We opportunities clinical medical excited very that that opportunity a really way, that group lie, so ensure understand to will to are from big leveraging the platform tuned. only refined in and from the where amassing respect

Day. and we plan at of information year more have Research as this Development you We a for end will the

Jeff Hung

you. thank Okay,

Operator

Thank you.

question Cowen. from of Thome comes next Our Joseph

is Your open. line

Joseph Thome

which XXXX, and into updated watch will taking my Hi guess the I guidelines look treatment what guess most? you then to your I largest you And and How we the in And did any guess bempedoic second, data? hopefully I do want increase scripts? have see I one Then be say does of want the data. there. you you. when for across talk to questions. wait you physicians, these helpful. events incorporation also the could to prescribe rates then morning label. when cause conversation as talk do go? that would to respond but they will to acid, we have you and the Outcomes they guess potentially we physicians, Good idea thank and on reorder Thank

Sheldon Koenig

the the end. that were of We out. at – last fading part Outcomes. got your for folks question, want you Joe, part but what of We got the second see kind to the faded

Joseph Thome

Yes.

reordering once rates, on they come staying on, Just therapy? patients on are

Sheldon Koenig

Yes. Joanne, do you want to?

Joanne Foody

So, for Joe, thank the you question.

is early line – what and there prescribe and those So, a results. with anticipate those year out, be the publication Outcomes, and of exactly the Understand waiting that voting already we guideline would and guidelines what will on to is likely that acid within have the anticipate we will, label XXXX. best importantly, And XXXX in bempedoic label. before that U.S. that for and have understanding if will our the for well would start awaiting right. process updated is would our the anticipate based be prevention inclusion that. in midyear results we the guidelines. top data present, time, a to Over have anticipate and give what we be we don’t We been their starts Clearly Ultimately, as would then, laid presentation individuals that we feet anticipate very but with We greatest will within course, you those us of significant you of see that who anticipate at but we have are do we then payers. have asterisk Outcomes, number says removed. guidelines we that label anticipate of the have one value, that

discuss a the to payers them would with talking strategy have and before to and data the label. will speak you did wins some we And want before However, prescriptions? the to well be well before anticipate Eric, with

Eric Warren

Yes.

for so much thanks So, question. the

comes to So, yes, from it sources. growth, the few with regards a

of also confirmed secondary some a Joanne’s and that or point, components statin we to yes, depth maximally patients. CLEAR with both tolerated quantitative of levers greater the or the penetration, penetration. It eliminating research. those dependence did on from those ASCVD the upon focus are So, the eliminating obviously significant We unlocked comes prevention access, And Outcomes. recently

significant opportunity thresholds. So, CLEAR Outcomes with two on those

Joseph Thome

Great. then on rates, therapy patients come on? And the on are just reorder staying once they

Eric Warren

perspective Yes. From consistent an adherence therapies. chronic adherence is oral with our very now,

we oral we but suite existing on on new patients, are called very are Next teams a chronic focused focused provide that improve on further therapies. Step, up So, to with of maintaining driving rate current also program of patients The therapy. coming will resources which a but adherence, with consistent

Joseph Thome

much. very you Thank Great.

Operator

Thank you.

comes of Tom from Shrader BTIG. question next Our

open. is line Your

Unidentified Analyst

in is Tom. This Sung calling morning. for good Hey,

for one just question me. So,

durability you. therapy additional LDL see the that’s So, guys much have studies or in combination wondering if you a acid, the achieve? showing the guys just with of can development drug I given any publications as how recent plans was long-term perform Thank to bempedoic to either additional already lowering approved you

Joanne Foody

So, you This morning. Thank good is question. for Joanne. the

demonstrating we just mentioned, have you extension recently benefit. as our published So, that open-label study consistent

I think combination the additional opportunity pursue tell And the right studies we now, CLEAR waiting really we then that are will not respect with whether or or therapies Outcomes. like. of for us to

of acid. as that the in well an generation of programs I the PCSKX well Importantly, all have opportunity as these know, discovery already informed presents next you bempedoic as as for And based will Outcomes as oral combination be think our we inhibitor phase, therapy. CLEAR on

to combine with of importance and that field, and other a growing is as cardiovascular positioned are to And say, you address oral the I NEXLIZET, patients. opportunity, bring existing I think think potentially there in the therapies our early combination NEXLETOL to therapies, with therapies oral well to we have risk. those

Unidentified Analyst

Great. Thank you.

Operator

Thank you.

Our from Choi Sachs. Please go of ahead. Paul next Goldman question comes

Paul Choi

maybe of commercial morning was a and return to Sheldon, seeing interactions say, time terms just direct are elaborate earlier maybe on you you sales comments of versus, questions. your to the office couple our how Thank Good regarding little your more the on team in-person face could give prescribers? interaction let’s gain – you for thanks sales is how last able color and progress. I patient And could wondering contract terms the is taking Congratulations in visits person just us of environment? you. your quarters seeing force and in in with as on force or if much in

Sheldon Koenig

turn then Eric. Thanks Paul. Yes. and start also will then it I a I over will take to

I the we know patients been been think a have back of to personally past think I weeks, what from office. having coming and definitely I So, couple seeing, office doctor’s are the to even

hearing are our large of with to practices open managers business of meeting or in all week again was I seeing are who had and them a last up patients just welcome large We speaking Philadelphia, Eric in. they even one areas –

a patients return there most think for people back of I the to office. So, bit where to still is a doing etcetera. part, balance starting telehealth, the are But are

am in okay, etcetera. the is their physicians to, actually I this, talk are to expert get are getting And this But open. more the access also, these news, about used representatives there able think with ability variants, to addressed. gain everyone, I Our is not I an where and healthcare know deal in

or a before don’t year environment like the see I what year ago a it being even So, that. was

And can Eric some be examples. talk just about overall would my that specific comments. So,

Eric Warren

Yes.

good So, your voice. Paul, hear to

not is is is small virtual It the focus Their team, for when again, a team. on a friendly. gives engaging team CSO flexibility which be times us virtually, as may environment good. the So,

engagement. want than say being leverage to it’s in-person really virtual personal And rather of an I Esperion both the kind in-person, would frequency. I reach, about the XX% also Our X% virtual promotion, team to extend or, an their team, improve and. their a it’s and to

perspective, XXXX see. of an up. direction. perspective, step in ACC. are Let’s I call, encouraged right it by a open an was ACC mentioned in was Obviously, to From wasn’t from the congresses it I earlier attendance environmental but as the starting

we that pure programs seeing smaller also conduct. more live peer-to-peer programs, groups We via larger lot such are in-person a speaker or as discussion

So, have not pillar as upon work the going encouraged the forward the really environment And completely important to changes. do promotional us the pillar flex right is I But by that a is team for be having that being any think I we but to model. dependent remain going balanced doing.

Paul Choi

for Thanks about type LDL and in program, believe? like patients. maybe Joanne, for MK-XXXX bit of maybe And as how to more They sort some development is you. which potential about to here Eric. Thank year Merck I at focus program, you one think last areas just AHA, oral your are think debut reduction just, relative you potential you XX% the how on development that which could had Great. there PCSKX will for you Okay. And just showing a comment little XX% on data of differentiation?

Joanne Foody

Yes.

much. you So, Paul, thank so

excited. are we So,

As we PCSKX have well and you oral impressive. very Merck mentioned, do the this was we aware data, of are which

better optimize development a we believe COGS. critical more have less the have the But we we that really almost that approach and us scaffold however, our believe and the development, be approach an an obviously and anything, we program. expensive PCSKX relatively with will think I with efficacy, our And inhibition if is accessible, is which smaller COGS critical. believe with importantly, in it’s that, And that, option. is as we we will allowing molecule allosteric Given for key oral about that allows think the which

So, stay tuned.

hoping the to have the for information scientific year. We the investor community later are community, in more

Paul Choi

you. Thank

Operator

you. Thank

from of Our Branchetti Wainwright. next H.C. question comes Emanuela

Your line is open.

Emanuela Branchetti

for my you taking and thank morning Good question. everyone

the of regarding or both in for launch you additional strategy their specific – the is question update launch any particularly color a drugs of you the there were Europe, Also, on that in their regions Perhaps launch Europe. geographies? could recently in added? more So, status provide in

Sheldon Koenig

Yes. Sure.

So, happy to.

good all, So, first of Emanuela. morning

Europe mentioned the in So Switzerland. there have is ave market. That’s the is in also They remarks, in very They market in actually, leading as we is largest The well. UK. our launched prepared Belgium. launched have They launched doing Germany.

Spain. in And I be soon, will they believe also

the have very been has launch we well. received As mentioned,

for label to exceeds dose are very about Now, have able on, be patients have. a that have the what And out being again, we done are allows to they they have have – and patients to there not patients use would the in number The label good who They PCSKXs on awareness for mind, maximum get actually out gain job NUSTENDI, in actually of on do And currently different statin. be whether a of than have who a that that number the of keep and Europe message. it PCSKX. or in NILEMDO been years. tolerated X

happy with And performance. very well together. we So, we our been work very have

it’s and them, with meetings very weekly a have collaboration. good We

Emanuela Branchetti

you Thank that. question what study. prognosis? for the ACS the a how study am Thanks. important lowering the how quick CLEAR perhaps a post percentage to what event is LDL-C you of I event that And post-ACS patient currently relevant understand LDL-C is guess only sense for Great. a regarding current give patients goals for us considered I positive care? this Could the of of achieve be with is outcome would the and standard trying physicians? And ACS

Joanne Foody

thank Emanuela, Yes. you so much.

is existing about the day, We one reasons. their post-ACS patients, ACS patients year, this in than we are many is know at for are that at XX% LDL less that that recommendation really therapies, goal. the excited appreciate we And post-ACS CLEAR despite not XX%. to a that still, But

to that’s in pragmatic the We high-risk care opportunity California even high particularly achieve And that’s short-term, better that NEXLIZET significant a their I a very amount very ACS, group to think a exactly achieved but that standard recognize bempedoic in LDL who this of to individuals we right. provide you in of a tremendous the our Can And therapy long-term. but with goals design system this LDL LDL achieve achieve respect it’s acid, existing with clinicians add patients. information to improve how cholesterol. proportion CLEAR combination So, study, LDL very Northern of goals will the to in of these patients. to ezetimibe, believe post-ACS goals study bar has but of

that helps. hopefully, So,

Emanuela Branchetti

Thank you. You bet.

Operator

Suisse. Judah Our from Frommer comes of next Instructions] Credit [Operator question

is open. Your line

Judah Frommer

the first the Thanks taking question. the of remind Hi. as you process the away in for for prescription? is offices changed? what Co-Pay you their physicians’ patient Yes. is support authorization could right And us from I the What expect was And prior patients have now how pandemic? Cards now? during just process have feedback with of you support place moved as can hoping

Joanne Foody

Sure, Judah.

offices process they So, had is found support well. our what XX% XX% place. of we about authorizations with in their of the But about have there offices And prior is do exquisitely own assist endeavor. prior do program this over we X,XXX with assistance together really program. And that offices with enrolled next-step have the put our We had now navigator that to authorization. in need patients

and on other seeing the products. refills from are on standpoint. staying offices and product pull-through used persistency And in host materials We a get patients a a we tactics really have and for of

authorizations the continue. we when those found authorizations the for right prescriptions authorizations, So, are the – the patient, prior documenting labeled And is, exact. with physicians are they are But prior through. and – patient go prior are the what the writing do right for then to

and concierge the back it’s and is have, but next-step go we the with also, the services then the with the behalf office. payer the forth service on physician’s to with will the it’s say it also of in And better. education, been patients, navigator, pleased So, going much offices, conduit almost

Judah Frommer

Okay. Thank you.

Operator

to back At closing this any remarks. like the call I turn Thank for you. would to Koenig time, Sheldon Sir? over

Sheldon Koenig

Great. Lateef. Thank you,

$XXX over great in the interest to And on current Esperion. their for want on conditions With that presentations want and bempedoic is patient educating the I future. actively our sheet, the well physicians these populations of study of thank will in positioned market So, about and day. the CLEAR beyond. balance are all, Outcomes first Esperion conference strategy again, to, thank in a execute acid come that again, everybody I the of capitalized we just million and everyone in ahead and everyone different remind to benefits Have

Operator

This you concludes for call. today’s Thank conference participating.

now disconnect. may You

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.